Anti-Human LAG-3 Recombinant Antibody (SAA0073) (HB613207)

Name: Anti-Human LAG-3 Recombinant Antibody (SAA0073)
Brand: abinScience
SKU: HB613207
Price: 191 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

50ug
100ug

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo	HB613207
Reactividad de especies	Human
Aplicaciones	FCM
Especie huésped	Human
Clonalidad	Monoclonal
Isotipo	IgG4, kappa
ID de clon	SAA0073
Objetivo	CD223, FDC, LAG-3, LAG3, Lymphocyte activation gene 3 protein, Secreted lymphocyte activation gene 3 protein, sLAG-3
Nivel de endotoxinas	< 10 EU/mg
Pureza	>95% as determined by SDS-PAGE.
Purificación	Protein A/G purified from cell culture supernatant.
Número de acceso	P18627
Forma	Liquid
Buffer de almacenamiento	0.01M PBS pH 7.4. Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Estabilidad y almacenamiento	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Fondo	Lymphocyte activation gene 3 protein (CD223/LAG3) is a ~57 kDa protein. Inhibitory receptor on antigen activated T-cells. Delivers inhibitory signals upon binding to ligands, such as MHC class II, its main ligand present at the surface of antigen-presenting cells (APCs), and FGL1, which is secreted by hepatocytes and certain types of tumor cells. Ligand-binding initiates a signaling that inhibits the T-cell receptor (TCR) in the immunological synapse, preventing T-cell activation. Mechanistically, ligand-binding promotes (1) ubiquitination of the KIEELE motif, unleashing the RRFSALE motif from the membrane and (2) leading to the formation of condensates with the TCR component CD3E, thereby disrupting the association between CD3E and LCK and preventing TCR activation. May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1. CD223 is the therapeutic target of relatlimab (Opdualag). 1. Camisaschi, C. et al. (2010) Journal of immunology (Baltimore, Md. : 1950) 184, 6545-51. PMID: 20421648 2. Ming, Q. et al. (2022) Nature immunology 23, 1031-1041. PMID: 35761082 3. Huard, B. et al. (1994) European journal of immunology 24, 3216-21. PMID: 7805750 4. Huard, B. et al. (1996) European journal of immunology 26, 1180-6. PMID: 8647185 5. Wang, J. et al. (2019) Cell 176, 334-347.e12. PMID: 30580966 6. MacLachlan, BJ. et al. (2021) European journal of immunology 51, 331-341. PMID: 32920841 7. Petersen, J. et al. (2024) Science immunology 9, eads5122. PMID: 39671469 8. Huard, B. et al. (1995) European journal of immunology 25, 2718-21. PMID: 7589152 10. Jiang, Y. et al. (2025) Cell 188, 2354-2371.e18. PMID: 40101708
Nota	For research use only.